We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
201
PUT
EyePoint Inc
EYPT
$989M
$386K 0.02%
89
+25
+39% +$942
FOCL
202
CALL
EDAP TMS S.A.
FOCL
$229M
$372K 0.02%
746
+246
+49% +$846
HZNP
203
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$346K 0.01%
219
– –
ARCT icon
204
PUT
Arcturus Therapeutics
ARCT
$161M
$344K 0.01%
+28
New +$3.38K
SEEL
205
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
FOLD
206
DELISTED
Amicus Therapeutics
FOLD
$334K 0.01%
+100,000
New +$235K
ADXS
207
PUT
DELISTED
Advaxis Inc
ADXS
$315K 0.01%
67
– –
OREX
208
DELISTED
Orexigen Therapeutics, Inc.
OREX
$309K 0.01%
5,000
+522
+12% +$30.4K
GLMD icon
209
Galmed Pharmaceuticals
GLMD
$4.42M
$306K 0.01%
174
– –
ALIM
210
PUT
DELISTED
Alimera Sciences
ALIM
$293K 0.01%
33
-36
-52% -$3.2K
PBYI icon
211
PUT
Puma Biotechnology
PBYI
$401M
$290K 0.01%
44
-227
-84% -$16.1K
TPH
212
DELISTED
Tri Pointe Homes
TPH
$290K 0.01%
+18,438
New +$298K
BSTG
213
DELISTED
Biostage, Inc. Common Stock
BSTG
$290K 0.01%
+27,730
New +$236K
TCRT icon
214
CALL
Alaunos Therapeutics
TCRT
$4.71M
$269K 0.01%
4
-1
-20% -$557
CEMP
215
CALL
DELISTED
Cempra, Inc.
CEMP
$268K 0.01%
250
+129
+107% +$1.25K
XOMA
216
CALL
DELISTED
Xoma
XOMA
$265K 0.01%
29
-25
-46% -$2.17K
PCYC
217
PUT
DELISTED
PHARMACYCLICS INC
PCYC
$260K 0.01%
29
-1,500
-98% -$141K
NWBO
218
CALL
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$254K 0.01%
378
-173
-31% -$1.1K
WINT
219
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$246K 0.01%
99
-2
-2% -$51
TENX icon
220
CALL
Tenax Therapeutics
TENX
$404M
– –
0
– –
MDCO
221
DELISTED
Medicines Co
MDCO
$231K 0.01%
+7,948
New +$212K
PRTA icon
222
PUT
Prothena Corp
PRTA
$441M
$226K 0.01%
100
-25
-20% -$625
NURO
223
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$226K 0.01%
+45
New +$228K
PRTA icon
224
Prothena Corp
PRTA
$441M
$221K 0.01%
+9,800
New +$245K
PGNX
225
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$211K 0.01%
490
-304
-38% -$1.16K
7 8
9
10 11

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.